Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media

Pediatr Infect Dis J. 2000 Feb;19(2):95-104. doi: 10.1097/00006454-200002000-00002.

Abstract

Objectives: To compare the bacteriologic and clinical efficacy of amoxicillin/clavulanate and azithromycin in patients with acute otitis media (AOM), particularly the ability to eradicate the predominant AOM pathogens from middle ear fluid as assessed by mandatory second tympanocentesis.

Methods: In this single blind study 238 infants and children with AOM were randomized to receive amoxicillin/clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days) or azithromycin (10 mg/kg on Day 1, then 5 mg/kg daily on Days 2 through 5). Tympanocentesis was performed before the first dose and repeated on Day 4, 5 or 6. Clinical response was assessed at end of therapy between Days 12 and 14 and at follow-up between Days 22 and 28.

Results: Amoxicillin/clavulanate was significantly more likely to eradicate all bacterial pathogens [83% (54 of 65) vs. 49% (35 of 71), P = 0.001] and Haemophilus influenzae [87% (26 of 30) vs. 39% (13 of 33), P = 0.0001] from middle ear fluid than was azithromycin. Amoxicillin/clavulanate was also more likely to eradicate Streptococcus pneumoniae, but the difference was not statistically significant [90% (18 of 20) vs. 68% (13 of 19) [corrected], P = 0.095]. On Days 12 to 14, signs and symptoms were more likely to resolve completely or improve in all culture-positive patients [86% (60 of 70) vs. 70% (51 of 73), P = 0.023] and in those with H. influenzae infections [91% (30 of 33) vs. 65% (22 of 34), P = 0.010] who received amoxicillin/clavulanate compared with those who received azithromycin. Otherwise there were no significant differences between groups in clinical outcomes on Days 12 to 14 or at follow-up.

Conclusions: Our findings indicate that amoxicillin/clavulanate has superior bacteriologic and clinical efficacy compared with azithromycin in children with AOM.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin-Potassium Clavulanate Combination / pharmacology
  • Amoxicillin-Potassium Clavulanate Combination / therapeutic use*
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use*
  • Child, Preschool
  • Female
  • Haemophilus influenzae / drug effects
  • Humans
  • Infant
  • Male
  • Microbial Sensitivity Tests
  • Moraxella catarrhalis / drug effects
  • Otitis Media with Effusion / drug therapy*
  • Otitis Media with Effusion / microbiology*
  • Penicillins / pharmacology
  • Single-Blind Method
  • Streptococcus pneumoniae / drug effects
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Amoxicillin-Potassium Clavulanate Combination
  • Azithromycin